Loading…

Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society a

On the basis of the information currently available, the only conditions in which GH therapy appears to be safe and effective in increasing adult height are GH deficiency and, likely, Turner syndrome. Therapy with GH also increases the growth velocity of children with CRI and may increase adult heig...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 1995-12, Vol.127 (6), p.857-867
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c314t-d806a08ed0941a0d73ba7764cfa89bc5ff3639de945ea06bdca531639cdc5bc73
cites
container_end_page 867
container_issue 6
container_start_page 857
container_title The Journal of pediatrics
container_volume 127
description On the basis of the information currently available, the only conditions in which GH therapy appears to be safe and effective in increasing adult height are GH deficiency and, likely, Turner syndrome. Therapy with GH also increases the growth velocity of children with CRI and may increase adult height, but no long-term data are available. Encouraging short-term results have been reported in patients with a few other conditions, such as patients with glucocorticoid-induced growth failure, renal transplantation, and Prader-Willi syndrome, but the data are limited and no long-term studies have been reported; in many other conditions the data are either inconclusive or discouraging. For children in these latter groups, GH therapy should be considered investigational and undertaken only as part of ethically sound, controlled clinical trials. Knowledge concerning the conditions in which GH is safe and effective is a prerequisite to making rational decisions concerning its use. However, in deciding whether therapy is warranted in an individual child, one must consider other important factors. The age and emotional maturity of the child, the family structure and dynamics, and even financial considerations may, in some cases, outweigh the presence of a GH-responsive condition. Likewise, the child's and the family's views about "short" stature and the likely benefits of therapy must be considered. Ultimately, a decision concerning the appropriateness of GH therapy must be individualized and based on a realistic assessment of its impact on the quality of life of the child and future adult.
doi_str_mv 10.1016/S0022-3476(95)70019-6
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77730790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347695700196</els_id><sourcerecordid>77730790</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-d806a08ed0941a0d73ba7764cfa89bc5ff3639de945ea06bdca531639cdc5bc73</originalsourceid><addsrcrecordid>eNo9UdGO0zAQjBDoKAefcNI-IXgIrOskTp7QqRwHUiWQ7hCPlmNvLobELrZD1W_iJ3F7FU8rzYxmd3aK4orhO4aseX-HuF6XvBLNm65-KxBZVzZPihXDTpRNy_nTYvVf8rx4EeNPROwqxIvioq3XnLW4Kv7eLtbQZB1FGHyANBIskcAP8BD8Po0w-jB7R2Ad6NFOJpCDvc1EzEyCmFRaAsE1BNodgf5wMvkYlgdQzsD9SEHtaElWR9j4ebYp0WnBUbZV--gd_LDTL-sifCNjVQpWw40zXod8F9x5bSkdQL0sng1qivTqPC-L759u7jefy-3X2y-b622pOatSaVpsFLZkclim0AjeKyGaSg-q7XpdDwNveGeoq2pS2PRGq5qzDGmj614Lflm8fvTdBf97oZjkbKOmaVKO_BKlEIKj6DALr87CpZ_JyF2wswoHef5u5j888pSv_WMpyJijOJ1DBtJJGm8lQ3msU57qlMeuZFfLU52y4f8Avf6U2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77730790</pqid></control><display><type>article</type><title>Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society a</title><source>ScienceDirect Journals</source><description>On the basis of the information currently available, the only conditions in which GH therapy appears to be safe and effective in increasing adult height are GH deficiency and, likely, Turner syndrome. Therapy with GH also increases the growth velocity of children with CRI and may increase adult height, but no long-term data are available. Encouraging short-term results have been reported in patients with a few other conditions, such as patients with glucocorticoid-induced growth failure, renal transplantation, and Prader-Willi syndrome, but the data are limited and no long-term studies have been reported; in many other conditions the data are either inconclusive or discouraging. For children in these latter groups, GH therapy should be considered investigational and undertaken only as part of ethically sound, controlled clinical trials. Knowledge concerning the conditions in which GH is safe and effective is a prerequisite to making rational decisions concerning its use. However, in deciding whether therapy is warranted in an individual child, one must consider other important factors. The age and emotional maturity of the child, the family structure and dynamics, and even financial considerations may, in some cases, outweigh the presence of a GH-responsive condition. Likewise, the child's and the family's views about "short" stature and the likely benefits of therapy must be considered. Ultimately, a decision concerning the appropriateness of GH therapy must be individualized and based on a realistic assessment of its impact on the quality of life of the child and future adult.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(95)70019-6</identifier><identifier>PMID: 8523180</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Acute Kidney Injury ; Adolescent ; Child ; Child, Preschool ; Contraindications ; Endocrinology ; Fetal Growth Retardation - drug therapy ; Growth Disorders - drug therapy ; Growth Hormone - adverse effects ; Growth Hormone - deficiency ; Growth Hormone - therapeutic use ; Humans ; Societies, Medical</subject><ispartof>The Journal of pediatrics, 1995-12, Vol.127 (6), p.857-867</ispartof><rights>1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c314t-d806a08ed0941a0d73ba7764cfa89bc5ff3639de945ea06bdca531639cdc5bc73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8523180$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><title>Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society a</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>On the basis of the information currently available, the only conditions in which GH therapy appears to be safe and effective in increasing adult height are GH deficiency and, likely, Turner syndrome. Therapy with GH also increases the growth velocity of children with CRI and may increase adult height, but no long-term data are available. Encouraging short-term results have been reported in patients with a few other conditions, such as patients with glucocorticoid-induced growth failure, renal transplantation, and Prader-Willi syndrome, but the data are limited and no long-term studies have been reported; in many other conditions the data are either inconclusive or discouraging. For children in these latter groups, GH therapy should be considered investigational and undertaken only as part of ethically sound, controlled clinical trials. Knowledge concerning the conditions in which GH is safe and effective is a prerequisite to making rational decisions concerning its use. However, in deciding whether therapy is warranted in an individual child, one must consider other important factors. The age and emotional maturity of the child, the family structure and dynamics, and even financial considerations may, in some cases, outweigh the presence of a GH-responsive condition. Likewise, the child's and the family's views about "short" stature and the likely benefits of therapy must be considered. Ultimately, a decision concerning the appropriateness of GH therapy must be individualized and based on a realistic assessment of its impact on the quality of life of the child and future adult.</description><subject>Acute Kidney Injury</subject><subject>Adolescent</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Contraindications</subject><subject>Endocrinology</subject><subject>Fetal Growth Retardation - drug therapy</subject><subject>Growth Disorders - drug therapy</subject><subject>Growth Hormone - adverse effects</subject><subject>Growth Hormone - deficiency</subject><subject>Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Societies, Medical</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNo9UdGO0zAQjBDoKAefcNI-IXgIrOskTp7QqRwHUiWQ7hCPlmNvLobELrZD1W_iJ3F7FU8rzYxmd3aK4orhO4aseX-HuF6XvBLNm65-KxBZVzZPihXDTpRNy_nTYvVf8rx4EeNPROwqxIvioq3XnLW4Kv7eLtbQZB1FGHyANBIskcAP8BD8Po0w-jB7R2Ad6NFOJpCDvc1EzEyCmFRaAsE1BNodgf5wMvkYlgdQzsD9SEHtaElWR9j4ebYp0WnBUbZV--gd_LDTL-sifCNjVQpWw40zXod8F9x5bSkdQL0sng1qivTqPC-L759u7jefy-3X2y-b622pOatSaVpsFLZkclim0AjeKyGaSg-q7XpdDwNveGeoq2pS2PRGq5qzDGmj614Lflm8fvTdBf97oZjkbKOmaVKO_BKlEIKj6DALr87CpZ_JyF2wswoHef5u5j888pSv_WMpyJijOJ1DBtJJGm8lQ3msU57qlMeuZFfLU52y4f8Avf6U2g</recordid><startdate>19951201</startdate><enddate>19951201</enddate><general>Mosby, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19951201</creationdate><title>Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society a</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-d806a08ed0941a0d73ba7764cfa89bc5ff3639de945ea06bdca531639cdc5bc73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Acute Kidney Injury</topic><topic>Adolescent</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Contraindications</topic><topic>Endocrinology</topic><topic>Fetal Growth Retardation - drug therapy</topic><topic>Growth Disorders - drug therapy</topic><topic>Growth Hormone - adverse effects</topic><topic>Growth Hormone - deficiency</topic><topic>Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Societies, Medical</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society a</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1995-12-01</date><risdate>1995</risdate><volume>127</volume><issue>6</issue><spage>857</spage><epage>867</epage><pages>857-867</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><abstract>On the basis of the information currently available, the only conditions in which GH therapy appears to be safe and effective in increasing adult height are GH deficiency and, likely, Turner syndrome. Therapy with GH also increases the growth velocity of children with CRI and may increase adult height, but no long-term data are available. Encouraging short-term results have been reported in patients with a few other conditions, such as patients with glucocorticoid-induced growth failure, renal transplantation, and Prader-Willi syndrome, but the data are limited and no long-term studies have been reported; in many other conditions the data are either inconclusive or discouraging. For children in these latter groups, GH therapy should be considered investigational and undertaken only as part of ethically sound, controlled clinical trials. Knowledge concerning the conditions in which GH is safe and effective is a prerequisite to making rational decisions concerning its use. However, in deciding whether therapy is warranted in an individual child, one must consider other important factors. The age and emotional maturity of the child, the family structure and dynamics, and even financial considerations may, in some cases, outweigh the presence of a GH-responsive condition. Likewise, the child's and the family's views about "short" stature and the likely benefits of therapy must be considered. Ultimately, a decision concerning the appropriateness of GH therapy must be individualized and based on a realistic assessment of its impact on the quality of life of the child and future adult.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>8523180</pmid><doi>10.1016/S0022-3476(95)70019-6</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3476
ispartof The Journal of pediatrics, 1995-12, Vol.127 (6), p.857-867
issn 0022-3476
1097-6833
language eng
recordid cdi_proquest_miscellaneous_77730790
source ScienceDirect Journals
subjects Acute Kidney Injury
Adolescent
Child
Child, Preschool
Contraindications
Endocrinology
Fetal Growth Retardation - drug therapy
Growth Disorders - drug therapy
Growth Hormone - adverse effects
Growth Hormone - deficiency
Growth Hormone - therapeutic use
Humans
Societies, Medical
title Guidelines for the use of growth hormone in children with short stature A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society a
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T04%3A41%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Guidelines%20for%20the%20use%20of%20growth%20hormone%20in%20children%20with%20short%20stature%20A%20report%20by%20the%20Drug%20and%20Therapeutics%20Committee%20of%20the%20Lawson%20Wilkins%20Pediatric%20Endocrine%20Society%20a&rft.jtitle=The%20Journal%20of%20pediatrics&rft.date=1995-12-01&rft.volume=127&rft.issue=6&rft.spage=857&rft.epage=867&rft.pages=857-867&rft.issn=0022-3476&rft.eissn=1097-6833&rft_id=info:doi/10.1016/S0022-3476(95)70019-6&rft_dat=%3Cproquest_pubme%3E77730790%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c314t-d806a08ed0941a0d73ba7764cfa89bc5ff3639de945ea06bdca531639cdc5bc73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77730790&rft_id=info:pmid/8523180&rfr_iscdi=true